Home › Funds › IRIDIAN ASSET MANAGEMENT LLC/CT › BCTX
IRIDIAN ASSET MANAGEMENT LLC/CT position in BCTX
BRIACELL THERAPEUTICS CORP · Health Care
IRIDIAN ASSET MANAGEMENT LLC/CT reported holding 65,000 shares of BCTX (BRIACELL THERAPEUTICS CORP) in its Q3 2026 13F filing — a position valued at US$278K, representing 0.10% of its reported portfolio and ranking #40 among its reported holdings. IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed BCTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How IRIDIAN ASSET MANAGEMENT LLC/CT's BCTX position evolved
IRIDIAN ASSET MANAGEMENT LLC/CT first disclosed a stake in BCTX in Q1 2026 at 65,000 shares (US$272K). The position peaked in Q3 2026 at 65,000 shares, worth US$278K. Across 3 filings, IRIDIAN ASSET MANAGEMENT LLC/CT held the position steady without any share-count change. The most recent filing (Q3 2026) shows 65,000 shares valued at US$278K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 65.00K | $272.35K | New |
| Q2 2026 | 65.00K | $210.60K | Hold |
| Q3 2026 | 65.00K | $278.20K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCTX and 13F data
BCTX (BRIACELL THERAPEUTICS CORP) is a Health Care company. 17 other funds we track also report a position in BCTX. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on IRIDIAN ASSET MANAGEMENT LLC/CT
FAQ
How long has IRIDIAN ASSET MANAGEMENT LLC/CT held BCTX?
IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed BCTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is IRIDIAN ASSET MANAGEMENT LLC/CT's current position in BCTX?
As of Q3 2026, IRIDIAN ASSET MANAGEMENT LLC/CT holds 65.00K shares of BCTX (BRIACELL THERAPEUTICS CORP), valued at $278.20K, representing 0.10% of its reported portfolio and ranking #40.
Has IRIDIAN ASSET MANAGEMENT LLC/CT been buying or selling BCTX?
In the latest 13F filing (Q3 2026), IRIDIAN ASSET MANAGEMENT LLC/CT held unchanged its position in BCTX. The position peaked in Q3 2026 at 65.00K shares.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.